Can a new drug calm the Gut's overactive immune response in Crohn's?

NCT ID NCT07753850

Not yet recruiting Disease control Sponsor: Shattuck Labs, Inc. Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 13, 2026 · Updated 3 times

Summary

This phase 2 trial is testing whether an investigational drug called SL-325 can help adults with moderate to severe Crohn's disease. The study will compare SL-325 against a placebo to see if it reduces gut inflammation and improves symptoms. Participants will receive the treatment intravenously over a period of about a year, with follow-up monitoring.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SL-325, an investigational drug given intravenously
What this could lead to: If successful, SL-325 could offer a new treatment option to reduce gut inflammation and improve symptoms in people with Crohn's disease.
What could go wrong: This is an early-phase trial, so the drug may not work as hoped or may cause side effects. Results from this study will need confirmation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN'S DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.